Nano Dimension (NNDM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
11 Jun, 2026Executive summary
An Extraordinary General Meeting is scheduled for July 31, 2026, to address several proposals affecting governance and board composition.
The meeting was called following a demand by a group of shareholders under Israeli law.
Shareholders of record as of June 23, 2026, are eligible to vote.
Voting matters and shareholder proposals
Proposal 1 seeks advisory approval for the continuation of the strategic alternatives review process; board recommends FOR.
Proposal 2, from shareholders, aims to amend Article 39 to declassify the board; board recommends FOR.
Proposals 3 and 4 propose adding new Articles 71 and 72; board recommends AGAINST.
Proposal 5 seeks removal of three directors; board recommends AGAINST.
Proposal 6, contingent on Proposal 5, seeks election of three new directors; board recommends AGAINST.
Proposal 2 requires a 70% majority; others require a simple majority of votes cast.
Board of directors and corporate governance
Board supports declassification (Proposal 2) but opposes removal and replacement of directors.
Director Phillip Borenstein disagrees with board recommendations on several proposals.
Board urges shareholders to disregard proxy materials from proposing shareholders.
Latest events from Nano Dimension
- Revenue up 46% to $58.7M, Q2 margin 45.9%, net loss widens, cost cuts to reduce cash burn.NNDM
Q2 2026 - Shareholders face a pivotal vote on Board control, with future input on strategic transactions.NNDM
Proxy filing - Proxy contest seeks board overhaul, annual elections, and more shareholder control over key decisions.NNDM
Proxy filing - Shareholders will vote on strategic direction, governance amendments, and board composition changes.NNDM
Proxy filing - Board supports strategic review and declassification, opposes governance and director changes.NNDM
Proxy filing - Proxy contest aims to declassify the board, restrict poison pills, and replace key directors.NNDM
Proxy filing - Proposed merger with Infinite Epigenetics offers a 20% premium and pivots to AI-powered diagnostics.NNDM
Proxy filing - $890M merger forms a Nasdaq-listed AI diagnostics leader targeting the $90–94B U.S. market.NNDM
M&A announcement - Q3 revenue surged 81% to $26.9M, but margins fell; Q4 guidance: $31.5M–$33.5M.NNDM
Q3 2025 - Record Q2 revenue, improved margins, and a transformative acquisition highlight best quarter.NNDM
Q2 2024